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Abstract
Breast cancer is the most frequently 
diagnosed malignancy in women in 
the United States. It is the second most 
common malignancy to cause death, 
with approximately 39,000 women 
dying of breast cancer in the United 
States in 2013.
Triple negative breast cancer is 
defined as the absence of estrogen, 
progesterone and human epidermal 
growth factor receptor 2 receptors. It 
has been associated with a higher 
incidence in African American women, 
a younger age and a more advanced 
stage at diagnosis, and an inferior 
overall survival.
To recognize the differences of our 
West Virginia community population 
when compared to the national 
average, we conducted a retrospective 
review of all patients diagnosed with 
breast cancer from 2000-2012.
Introduction
Breast cancer is the most 
frequently diagnosed malignancy in 
women in the United States.1 There 
were 232,340 women diagnosed 
with breast cancer in 2013. This 
accounts for 29% of new cancer 
cases. It is the second most 
common malignancy causing death 
with 39,620 women dying of breast 
cancer in the United States in 2013.2 
A breast cancer tumor is 
characterized by the presence or 
absence of the estrogen receptor 
(ER), progesterone receptor (PR), 
and/or human epidermal growth 
factor receptor 2 (HER2). These 
biomarkers have a predictive and 
prognostic value in the course of 
treatment. Triple negative breast 
cancer (TNBC) is defined as the 
absence of all three receptors and 
accounts for 10-20% of the newly 
diagnosed breast cancers globally.3
Triple negative breast cancer 
has also been associated with 
racial disparities. African American 
women are found to have a higher 
incidence of TNBC when compared 
to Caucasian and Hispanic women 
(OR 2.98, 95% CI 2.12-4.20).4-5 
Women diagnosed with triple 
negative disease tend to be of 
younger age (34% were 18–29 
years of age), lower socioeconomic 
status, and are more obese when 
compared to hormone positive 
tumors (ER/PR+, HER2 negative).4-5 
Triple negative tumors have been 
found to have distinct features when 
compared to non-triple negative 
cancers including: larger in size, 
higher nodal positivity, higher 
advanced stages, more lympho-
vascular invasion and higher 
percentages of poorly differentiated 
tumors.5-6 These tumors have also 
been shown to have an inferior 
cancer-specific and overall survival 
(OS) with the highest risk of death 
within the first two years after 
diagnosis (breast cancer-specific 
survival: HR 8.30; 95% CI, 6.23-
11.05) (OS: HR 6.10; 95% CI, 4.81-
7.74).7 Women with triple negative 
tumors are more likely to have higher 
rates of visceral metastases, brain 
metastases, lung and loco-regional 
metastases, but have been found 
less likely to have bone metastases.7 
To understand the differences of 
our Tri-State community population 
(West Virginia and it’s neighboring 
states Kentucky and Ohio) 
compared to the national average, 
we conducted a retrospective 
review of all patients diagnosed 
with breast cancer from 2000-
2012. Our goal was to assess the 
differences and survival outcomes 
between triple negative breast 
cancer and all other types of 
hormone positive disease in our 
community-based hospital practice. 
Methods and Data Review
This is a retrospective chart review 
of patients diagnosed with breast 
cancer at Marshall University/Cabell 
Huntington Hospital from 2000-2012. 
The purpose was to assess the 
differences in survival and stage 
at diagnosis among hormone 
positive (ER/PR positive), HER2 
positive, Triple Positive (ER/PR/
HER2 + and ER/HER2 +), and 
Triple Negative disease (ER/PR/
HER2 negative) in a 12 year period. 
Patient information was accessed 
through our hospital Breast Cancer 
Registry Database. Data collected 
included tumor hormone status, age 
of the patient at diagnosis, race, 
family history of breast cancer, 
stage of tumor at diagnosis, date 
of diagnosis, year the patient was 
deceased or if the patient is still 
alive at date of last contact, and 
treatment if applicable. Patients with 
DCIS, LCIS, missing pathology and 
hormone status were excluded. 
The time interval between the date 
of diagnosis and date of death or 
last contact was calculated in days. 
Each individual pathology report 
was verified for hormone status 
and diagnosis of breast cancer. 
The patients were divided into 4 
groups: Hormone Positive (ER/
PR positive), HER2 positive, Triple 
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Positive, and Triple Negative for 
analysis. Patient characteristics were 
assessed for stage at diagnosis, 
family history of breast cancer, 
and survival. Local disease was 
defined as Stage I and Stage II, 
regional disease as Stage III and 
metastatic disease as Stage IV. 
Local disease included Stage I and II 
disease together due to their similar 
treatment regimens, and overall 
survival. The primary endpoint 
was a two and five year overall 
survival by hormone/HER2 receptor 
status among the four groups. 
Results
This retrospective review included 
1,022 patient charts from 2000-
2012 that were diagnosed with 
breast cancer at Cabell Huntington 
Hospital. Seventy two percent of 
the patients were hormone positive 
(ER/PR positive), while 14% of the 
population was diagnosed with 
triple negative disease (Table I). 
Seven hundred and ninety patients 
presented with local disease (Stage 
I+II), 111 with regional disease 
(Stage III), 74 with metastatic 
disease (Stage IV) and 47 had 
missing information. Thirty percent 
of the African American population 
was diagnosed with triple negative 
disease (9/30) in comparison to only 
14% of the Caucasian population 
(134/983). A large proportion of 
African Americans were also 
diagnosed with HER2 positive 
disease (13%) versus only 5% of 
the Caucasian population (Table 
II). SEER database information 
from 1995-2009 documents that 
the incidence rate of breast cancer 
was found to be the highest in 
the United States in Kentucky 
(523.1/100,000 patients) with West 
Virginia and Ohio not too far behind 
(496.8/100,000 and 470.8/100,000 
patients respectively).2 
The median age at diagnosis 
for triple positive disease was 53 
years old, while the median age 
at diagnosis for triple negative, 
hormone positive and HER2 positive 
were 58 years old, 60 years old and 
60 years old, respectively. When 
comparing our patients to a nearby 
facility (West Virginia University - 
WVU), the mean age at diagnosis 
was 51.7 years old for the triple 
negative hormone group versus 
58.2 years old in the other hormone 
combination groups.8
Patients in each group reported 
a significant family history of 
breast cancer in a first degree 
relative, ranging from 62% in the 
Who says you can’t have it all? 
When Dr. Randy Katz joined TeamHealth, he wanted to be part of 
a group with national resources, physician-focused management, 
a network of respected peers, long-term stability and a formalized 
leadership training program. He also wanted to protect cherished 
time for his family and hobbies. With TeamHealth, he got it all.   
Visit TeamHealth.com to find  
the job that’s right for you.
888.861.4093      physicianjobs@teamhealth.com
Your career. Your way.
Hormone Status Number of 
Patients (%) 
N=1022
Hormone Positive (ER or PR Positive) 735 (71.9)
Triple Negative 144 (14.1)
Triple Positive (including ER/HER2 Positive) 88 (8.6)
HER2 Positive 55 (5.4)
Table I – Number of Breast Cancer Patients Separated by Hormone Status
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HER2 positive group to 76% in 
the triple negative group. Using a 
Pearson Chi-Squared test, patients 
presenting with triple negative 
breast cancer were compared 
to non-triple negative disease 
showing no correlation between 
family history and the incidence of 
TNBC (p value = 0.10) (Table III).
We were unable to identify the 
number of patients and their race by 
state distribution at our institution. 
Data reviewed from WVU also did 
not delineate patients by race or 
state distribution. The population of 
the Tri-State area at our institution 
consisted mostly of Caucasian 
females (Table II). However, the 
rate of African American patients 
diagnosed with triple negative 
disease was significantly higher 
when compared to the Caucasian 
population (30% vs. 13.6%, 
respectively; p value = 0.04). This 
demonstrates that our population of 
African American females presented 
with a more aggressive disease 
subtype at initial diagnosis. 
Overall survival (OS) was 
evaluated and results adjusted 
by stage and hormone/HER2 
status (Figure I). Stage IV breast 
cancer was associated with the 
worst overall survival at just under 
25% alive at 5 years (p value 
<0.001). Subset analysis revealed 
that survival was also drastically 
decreased at 2 years for our patients 
diagnosed with Stage IV disease, 
either HER2 positive or triple 
negative, at time of presentation 
(26.7% and 32.3% respectively). 
This poor overall survival was in 
comparison to all other hormone 
groups and existed despite early 
diagnosis and early stage at 
presentation (p value <0.001 for both 
groups) (Figure II). When evaluating 
the five year overall survival for 
the triple negative disease group 
versus all other hormone/HER2 
groups with local disease (Stage 
I+II) and regional disease (Stage 
III), there was a significant decrease 
in survival for the TNBC group 
at each stage (p value 0.03 and 
0.02 respectively) (Figure III).
The unadjusted overall mortality 
of triple negative breast cancer 
patients when calculated by the Cox 
Regression Model was significantly 
increased (HR of 1.803, CI 1.289 
– 2.52; p = 0.001). When adjusted 
for stage and age at diagnosis, 
TNBC patients were found to be 
2.1 times more likely to die of their 
disease when compared to all 
other hormone/HER2 groups (p 
value < 0.0001; CI 1.455-2.936). In 
comparison, triple negative breast 
cancer patients studied in the 
National Comprehensive Cancer 
Network group showed an OS 
hazard ratio of 2.72 (p <0.0001) 
after adjusting for age, stage, 
race and other tumor factors.7
Discussion
Triple negative breast cancer 
(TNBC) is a challenging clinical 
condition. Systemic therapy for these 
patients is limited to conventional 
chemotherapy due to the lack of 
hormone and HER2 receptors. In 
this regional retrospective data 
analysis, TNBC patients were 
compared to non-TNBC patients 
to identify the disparities and 
outcomes among each group.
Triple negative breast cancer 
occurred in 14% of the study 
population with a similar rate 
reported in another article published 
by West Virginia University.8 African 
Americans with breast cancer 
represented only 3% of our study 
population. This demonstrates the 
demographic difference of our region 
when compared to national data 
by the Centers for Disease Control 
and Prevention, which reported 
that African Americans represent 
about 14% of the population with 
breast cancer.9 Despite such an 
underrepresented population in 
this study, TNBC had a higher 
prevalence in the African American 
group (30% or 9/30) when compared 
to other non-triple negative breast 
cancer groups. This observation was 
consistent with a California cancer 
registry review published by Amirikia 
et al.10, which revealed that African 
Americans developed the highest 
Hormone Status Caucasian African American Other P Value
N (%)
Fisher’s Exact Test = 
0.04
Hormone Positive (ER/PR +) 714 (72.6) 14 (46.7) 7 (77.8)
Triple Negative 134 (13.6) 9 (30) 1 (11.1)
Triple Positive (including ER/HER2+) 84 (8.6) 3 (10) 1 (11.1)
HER2 Positive 51 (5.2%) 4 (13.3) 0 (0)
Table II – Patient Characteristics by Race and Hormone Status
Family History of Breast Cancer Triple Negative Non-Triple Negative
Pearson Chi Square Test
P = 0.10
Number (%)
Yes 109 (75.7) 60 (68.2)
No 31 (21.5) 22 (25)
Missing 4 (2.8) 6 (6.8)
Table III – Patients Reporting a Family History of Breast Cancer, Triple Negative vs. Non-Triple Negative
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rate of triple negative disease 
when compared to Hispanics and 
Caucasians at all age groups. 
Contrary to other reports4-5,11, the 
women with triple negative disease 
in our study had a non-statistically 
significant lower median age at 
diagnosis when compared to the 
hormone positive (ER/PR +) and 
the HER2 + only groups (58 years 
old and 60 years old, respectively). 
Furthermore, triple positive (ER+/
PR+/HER2+ or ER/HER2+) patients 
had a median age at diagnosis that 
was lower than the TNBC patients 
(53 years old versus 58 years old). 
When comparing these results to 
other institutions in West Virginia, 
our triple negative breast cancer 
patients are presenting at a later 
age on average when compared to 
other women diagnosed with triple 
negative breast cancer at other 
facilities (58 years old vs. 51.7 
years old).8 A probable explanation 
for this disparity may be due to the 
small sample size of this study. 
Family history is a well-known 
risk factor for breast cancer. Among 
all groups in our study, a positive 
family history was reported at 
higher rates when compared with 
a study by the Collaborative Group 
on Hormonal Factors in Breast 
Cancer, which reported a family 
history of breast cancer between 
7-12%.12 The rate of positive family 
history of breast cancer in our 
triple negative patient population 
was 75.7%. Despite having a 
significant proportion of patients with 
a family history of disease, there 
was no correlation between triple 
negative disease and a positive 
family history as documented by a 
Pearson Chi Square test (p=0.10). 
BRCA mutational status was not 
analyzed due to lack of reporting 
in the Tumor Registry database.
Studies by Dent et al and Lin et 
al reported a more advanced stage 
of disease at diagnosis (i.e Stage 
IV) for triple negative breast cancer 
patients when compared to other 
hormone groups.6-7 Even though 
TNBC has been reported to be more 
aggressive, our study revealed that 
our triple negative breast cancer 
population presented at the time of 
diagnosis with more local disease 
(Stage I+II – 74%) rather than 
advanced disease (Stage III or IV – 
22%). This finding may be related 
to campaigns for breast cancer 
screening and good surveillance 
by physicians and patients in the 
area, especially in those whom 
a family history is known. 
The two year overall survival in 
early stage breast cancer patients 
(Stage I+II) was similar among 
all hormone positive groups, with 
triple negative and HER2 positive 
only disease being slightly lower 
at 91.6% and 88.5%, respectively. 
Multiple reviews have confirmed 
that TNBC patients have an overall 
inferior outcome.5-7, 10 The Stage IV 
Figure I. Five Year Overall Survival by Stage of Disease at Diagnosis
Figure II. Two Year Overall Survival for Stage IV Disease by Hormone 
Group
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triple negative breast cancer group 
in our study had an overall poorer 
outcome when compared to the 
other hormone positive groups (p 
< 0.001), but not when compared 
to the HER2 positive only group. 
However, when comparing the HER2 
positive group to all other hormone 
groups (excluding triple negative 
disease), the overall survival was 
inferior for the HER2 positive group 
(p value of <0.001). The study 
by Amirikia et al documented a 
worse overall survival at 5 years 
for African Americans when 
compared to Caucasian females 
(117 months vs. 166 months; p < 
0.001).10 The worse OS found in 
our retrospective review may be 
related to environmental factors, 
socioeconomic status and ability to 
reach adequate care. Patients in 
the Tri-State area sometimes travel 
great distances (up to 3 hours) 
to reach the hospital for care. 
Multiple studies from the 1990s 
have documented a decrease in 
response rate to endocrine therapy 
and chemotherapy in patients 
who were hormone positive (ER/
PR+) and also HER2 positive.13-15 
In vitro studies performed found 
that higher levels of the c-erbB2 
proto-oncogene associated with 
the HER2 receptor status promoted 
resistance to endocrine therapy and/
or chemotherapy and may have 
contributed to less than expected 
results from anti-HER2 therapy.14-15
Major limitations of this report 
were that it was a retrospective study 
with a small number of patients.
Conclusion
Consistent with national data, the 
overall survival outcome of patients 
with triple negative breast cancer 
in our rural population was inferior 
when compared to patients with 
hormone positive disease, however 
the OS of the triple negative 
hormone group was not as poor as 
the national data (OS hazard ratio 
2.07 vs. 2.72, respectively). This 
likely is due to the small number of 
patients included in this review. 
The higher incidence of triple 
negative breast cancer in our African 
American female population was 
also consistent with national data. 
In contrast, the higher incidence 
of family history and advanced 
stage of disease at diagnosis did 
not correlate with the incidence 
of triple negative breast cancer in 
our retrospective study. Patients in 
this study had a higher degree of 
family history of breast cancer and 
presented at an earlier stage at time 
of diagnosis likely due to effective 
screening and patient awareness. 
Further studies are warranted 
to discover more effective 
therapy for this poor outcome 
population of breast cancer.
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